Go back to the erosion equation and ask the obvious question. What sets the erosion rate? Almost entirely, it's how many companies can legally and physically make the product. Price collapses toward marginal cost only when enough sellers arrive to compete it down. So the art of earning a return on the treadmill is picking products the crowd can't copy, and complexity is the barrier that keeps the crowd out.
Why does product complexity mean higher margin?
Walk up the complexity ladder, watching the competitor count fall and the price hold:
| Form | Why it's hard | Typical competitors | Erosion |
|---|---|---|---|
| Simple oral solid (tablet/capsule) | Anyone with a plant + a GDUFA fee | 8–15 | 80–95% price collapse |
| Modified-release / fixed-dose combination | Formulation know-how | 4–8 | Moderate |
| Injectables / sterile | Sterile manufacturing is genuinely hard; shortage-prone | 2–5 | Low; price can rise on shortages |
| Ophthalmics, topicals/dermatology | Device + bioequivalence difficulty | 2–5 | Low |
| Respiratory (inhalers, nasal), transdermals | Must often prove equivalence with clinical endpoint trials, not just blood-level PK | 1–3 | Very low; years of exclusivity in practice |
| Peptides, complex/long-acting injectables | Chemistry + delivery | 1–3 | Very low |
| Biosimilars | A different universe (below) | 1–4 | Slow, partial |
Advertisement
Worked contrast: the same brand, two ways (synthetic). Take a $600m/year brand losing exclusivity. Compare a plain oral generic with a complex injectable version of an equivalent molecule.
- Simple oral solid. Ten entrants arrive inside a year. Price settles at ~10% of brand and your volume share is ~12%. Steady-state revenue = 600 × 0.12 × 0.10 = $7.2m. At a gross margin of ~45% that's ~$3.2m of gross profit, still eroding a few points a year.
- Complex injectable. Only three entrants turn up. Sterile capacity and a hard bioequivalence path keep the crowd out. Price holds at ~45% of brand and your share is ~30%. Steady-state revenue = 600 × 0.30 × 0.45 = $81m. At a gross margin of ~60% that's ~$49m of gross profit, eroding only 2–4% a year.
Same brand size, yet you get an eleven-fold revenue difference and a fifteen-fold gross-profit difference, created entirely by how many companies can make the thing. So the "complex generics / injectables mix" KPI is far more than a footnote. It separates a business on a treadmill from a business with a short, real moat, a cornered manufacturing capability made of stainless steel and regulatory approvals. In Helmer's terms it's process power plus a cornered resource.
How are biosimilars different from complex generics?
Biosimilars are the frontier, where complexity becomes a fortress. Biologics are large molecules grown in living cells (monoclonal antibodies, insulins, fusion proteins). You can't make an exact copy of a cell-made molecule, so the copy gets a different name, a biosimilar, and the whole Hatch-Waxman shortcut doesn't apply. Instead:
- Pathway and cost. The US route is the BPCIA 351(k) pathway (Biologics Price Competition and Innovation Act, 2010), and Europe (EMA) pioneered it a decade earlier. Development runs $100–300m and 7–10 years, with real clinical trials. That's two orders of magnitude more than a $1–5m oral ANDA, and the cost itself is the moat, since only a handful of scaled players can play.
- No automatic substitution. Small-molecule generics are auto-substituted at the US pharmacy counter. Biosimilars generally aren't, unless they earn a separate "interchangeable" designation. Uptake is therefore physician-driven and slow.
- Gentle erosion. With few players and no auto-substitution, biosimilar price erosion is 15–40% over several years, against 80–95% in months for a simple generic, and volume builds gradually. The adalimumab (Humira) biosimilar wave from 2023 is the live case study. Even against the best-selling drug in history, erosion came in stages, with no cliff.
For a scaled Indian player, biosimilars are the strategic escape from the treadmill. Think of a Biocon-style biosimilars franchise, or Dr Reddy's and Cipla building biosimilar pipelines (illustrative). The barriers are enormous and the margins durable. The market is measured in tens of billions of dollars of biologics losing exclusivity this decade. And the cost of admission that keeps others out is what makes you safe once you're in.